Form 4: Spyre Therapeutics CFO Granted Stock Options

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, was granted stock options for 95,500 shares on January 15, 2025.

Summary

• Scott L. Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc., was granted stock options to purchase 95,500 shares of the company's common stock.
• The options were granted on January 15, 2025, at an exercise price of $21.66 per share.
• The options vest in equal monthly installments over four years, contingent upon Mr. Burrows' continued employment with the company.
• The options expire on January 15, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued employment and commitment from the CFO.

Risks

• The value of the stock options is dependent on the future performance of Spyre Therapeutics' stock price.
• If Mr. Burrows leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next four years, subject to the CFO's continued employment.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of four years is also typical, designed to retain key personnel and encourage long-term value creation.
• The exercise price of $21.66 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, CFO, Spyre Therapeutics, equity